Finished product reference
Desonide
Ointment · Topical · 0.05 % · 15 g
- List code
- 52670
- Pharmacologic class
- Corticosteroid
What it is and how it works
Mechanism class: Corticosteroid Hormone Receptor Agonists
Indications
INDICATIONS AND USAGE Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
Dosage and administration (summary)
DOSAGE AND ADMINISTRATION Desonide Ointment, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide Ointment, 0.05% should not be used with occlusive dressings.
Contraindications
CONTRAINDICATIONS Desonide Ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Pregnancy
PREGNANCY Teratogenic effect Pregnancy Category C - Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
Storage and supply
HOW SUPPLIED Desonide Ointment, 0.05% is available as follows: 60 g tube (NDC 63629-8481-1) Store at 20-25°C (68-77°F) . Repackaged/Relabeled by: Bryant Ranch Prepack Burbank, CA 91504
Source: Desonide Ointment, 0.05% (Desonide Ointment, 0.05%) — US FDA prescribing information, 2026-05-28, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.